Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Fifty-nine patients were enrolled in the KINECT-PRO study and received once-daily INGREZZA (40 mg, 60 mg or 80 mg) for up to 24 weeks. Fifty-two patients completed the Week 24 visit. There were ...

2024 marked a significant milestone for Neurocrine with INGREZZA achieving record sales, showing an impressive increase of approximately $475 million. This robust performance underscores the drug ...